Premium
Ototoxic Impact of Cisplatin in Pediatric Oncology Patients
Author(s) -
Berg Abbey L.,
Spitzer Jaclyn B.,
Garvin James H.
Publication year - 1999
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1097/00005537-199911000-00016
Subject(s) - audiology , medicine , hearing loss , audiometry , sensorineural hearing loss , ototoxicity , audiogram , cisplatin , chemotherapy , surgery
Objective: To describe hearing changes in a group of 28 children (age range, 8‐180 mo) undergoing protocol‐based cisplatin therapy. Methods: Conventional, play audiometry, visual reinforcement audiometry (VRA), immittance audiometry, transient click evoked otoacoustic emissions (OAEs), and auditory brainstem response (ABR) evoked potentials were used to assess peripheral sensitivity and for threshold determination. Results: Bilateral symmetrical high‐frequency sensorineural hearing loss was noted in 9 of the 28 children (26%). Hearing loss was evident as early as 1 month after chemotherapy and as late as 50 months and was not dependent on individual or cumulative dosage of cisplatin. Conclusions: 1) Presence of sensorineural hearing loss was independent of individual and/or cumulative dosage of cisplatin; 2) audiologic assessment should be incorporated into a child's periodic medical evaluations after chemotherapy treatment, as onset of sensorineural hearing loss cannot be predicted; 3) personal hearing aids may be indicated for those children with hearing loss affecting the low‐ to mid‐frequencies; a personal assistive listening device (frequency modulated system) may be more appropriate for losses above 3000 Hz; and 4) evaluation and intervention by a speech‐language pathologist may be indicated to address possible articulation or language development problems consequent to hearing loss.